Wegovy
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Wegovy?
Semaglutide for weight management, approved by the FDA in 2021 as a weekly injection that climbs from 0.25 mg to a usual 2.4 mg (some adults can go up to 7.2 mg), and now also sold as a daily tablet with a 25 mg maintenance dose.
The label also covers cardiovascular risk reduction and, for the injection, MASH with liver fibrosis. It is the same molecule as Ozempic at a higher top dose. When you shop, remember that a compounded seller advertising “semaglutide” is not selling you Wegovy, and the price gap between the two is the largest in this market.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Wegovy comes up on this site
On GLP Watchdog, Wegovy comes up in 127 research articles, 135 seller reviews, 9 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Does Delaware Medicaid Cover Wegovy and Zepbound? Yes, With a Health-Condition Rule
- Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers
- Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On
- How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
- How Long Do Zepbound, Wegovy and Other GLP-1s Stay in Your System?
- Phentermine vs Ozempic, Wegovy and Zepbound: Is Phentermine a GLP-1?
- All 127 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers